Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | RO7198457 |
Synonyms | |
Therapy Description |
RO7198457 is a personalized neoantigen-specific immunotherapy that stimulates T-cell mediated immune response against tumor cells, potentially resulting in antitumor activity (Cancer Res (2020) 80 (16_Supplement): CT301). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7198457 | RG 6180|RG-6180|RG6180|RO-7198457|RO 7198457 | RO7198457 is a personalized neoantigen-specific immunotherapy that stimulates T-cell mediated immune response against tumor cells, potentially resulting in antitumor activity (Cancer Res (2020) 80 (16_Supplement): CT301). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03289962 | Phase I | RO7198457 Atezolizumab + RO7198457 | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | ESP | DEU | CAN | BEL | 3 |
NCT04486378 | Phase II | RO7198457 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Recruiting | USA | ESP | DEU | BEL | 0 |